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AbstrACt
Objective Recent studies suggest that a systolic blood 
pressure (SBP) target of 120 mm Hg is appropriate for 
people with hypertension, but this is debated particularly 
in people with multiple chronic conditions (MCC). We 
aimed to quantitatively determine whether benefits of a 
lower SBP target justify increased risks of harm in people 
with MCC, considering patient-valued outcomes and their 
relative importance.
Design Highly stratified quantitative benefit-harm 
assessment based on various input data identified as the 
most valid and applicable from a systematic review of 
evidence and based on weights from a patient preference 
survey.
setting Outpatient care.
Participants Hypertensive patients, grouped by age, 
gender, prior history of stroke, chronic heart failure, 
chronic kidney disease and type 2 diabetes mellitus.
Interventions SBP target of 120 versus 140 mm Hg for 
patients without history of stroke.
Primary and secondary outcome measures Probability 
that the benefits of a SBP target of 120 mm Hg outweigh 
the harms compared with 140 mm Hg over 5 years 
(primary) with thresholds >0.6 (120 mm Hg better), <0.4 
(140 mm Hg better) and 0.4 to 0.6 (unclear), number of 
prevented clinical events (secondary), calculated with the 
Gail/National Cancer Institute approach.
results Considering individual patient preferences had 
a substantial impact on the benefit-harm balance. With 
average preferences, 120 mm Hg was the better target 
compared with 140 mm Hg for many subgroups of patients 
without prior stroke, especially in patients over 75. For 
women below 65 with chronic kidney disease and without 
diabetes and prior stroke, 140 mm Hg was better. The 
analyses did not include mild adverse effects, and apply 
only to patients who tolerate antihypertensive treatment.
Conclusions For most patients, a lower SBP target 
was beneficial, but this depended also on individual 
preferences, implying individual decision-making is 
important. Our modelling allows for individualised 
treatment targets based on patient preferences, age, 
gender and co-morbidities.
bACkgrOunD
Recommended blood pressure targets for 
people with multiple chronic conditions 
(MCC) and hypertension vary across guide-
lines.1–4 The recent publication of three 
randomised clinical trials (RCTs), ACCORD 
in people with diabetes,5 SPRINT in people 
without diabetes6 and SPS3 in people with 
strengths and limitations of this study
 ► This is the first comprehensive benefit-harm as-
sessment of systolic blood pressure targets in 
people with multiple chronic conditions (MCC), con-
sidering patient-valued outcomes and their relative 
importance.
 ► The model is based on the most valid and applicable 
data from a systematic review of evidence, and on a 
patient preference survey to inform the relative im-
portance of outcomes.
 ► Analyses were stratified by age, gender and prev-
alent comorbidities, and additionally by individu-
al preferences in a sensitivity analysis, to clarify 
whether the benefit-harm balance of systolic blood 
pressure targets depends on individual preferences.
 ► Due to lacking evidence we could not include all 
patient-valued outcomes, in particular mild adverse 
events – therefore, the results apply only to people 
who tolerate antihypertensive treatment.
 ► Techniques to measure the blood pressure differed 
between trials and may differ between trials and 
clinical practice, therefore, an interpretation of what 
would be the analogous targets in clinical practice 
may be required.
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lacunar stroke,7 caused debate in the medical community 
about the benefits and harms of systolic blood pressure 
(SBP) targets lower than 140 mm Hg, since lower targets 
reduced the risk of some cardiovascular outcomes, but 
increased the incidence of adverse events, and because the 
effect on mortality differed across the RCTs.5–8 Concerns 
were voiced that the absolute benefit of lower SBP targets 
is small and may not outweigh the absolute harm, espe-
cially in older adults with MCC.9 Furthermore, techniques 
to measure the blood pressure differed between trials and 
may differ between trials and clinical practice.1 10
The question of which blood pressure target is optimal 
for people with MCC and whether this differs for some 
groups of people was recently identified as a priority ques-
tion by people with MCC and caregivers in a multi-step, 
mixed-methods process involving guideline developers.11 
The benefit-harm balance depends on the baseline 
incidence for different outcomes, the relative effect of 
different targets and the relative importance of potential 
benefit and harm outcomes to the patient.12 13 Clinical 
guidelines often consider these three key elements when 
developing recommendations but often do so unsystem-
atically and qualitatively. The National Cancer Institute 
has developed methods for quantitative benefit-harm 
assessment to elucidate the benefit-harm balance of treat-
ment alternatives in a systematic and transparent way.13 14 
Using such methods, the absolute beneficial and harmful 
effects on different outcomes are weighed and compared 
on a common scale.
In order to determine the benefit-harm balance of 
different blood pressure targets specifically for people 
with MCC, and to clarify whether the balance depends 
on baseline characteristics or outcome preferences, we 
performed quantitative assessments for a priori defined 
subgroups based on age, gender, prior history of stroke, 
chronic kidney disease (CKD), diabetes and chronic 
heart failure.
MethODs
study design
We performed a quantitative benefit-harm assessment 
and followed the Consolidated Health Economic Eval-
uation Reporting Standards for cost-effectiveness anal-
yses.15 We modelled the benefit-harm balance in different 
subgroups according to the Gail/National Cancer Insti-
tute approach13 that has been used before to assess various 
prevention treatments.16–19 This method calculates abso-
lute risk differences of treatments (ie, the difference in 
expected number of events for each outcome) from base-
line incidence and relative effects and weighs the abso-
lute risk differences on different outcomes according to 
their importance relative to each other. Importantly, it 
considers competing risks (eg, death), and the statistical 
uncertainty of input parameters.
Definition of the target population, subgroups and outcomes
The target population was people age 50 and older with 
hypertension and multiple chronic conditions in the 
USA. Based on patient and caregiver input and clinical 
judgement, we predefined subgroups according to prev-
alence and possible impact on the benefit-harm balance: 
age, gender, prior history of ischaemic stroke, CKD, type 
2 diabetes mellitus and chronic heart failure. Based on 
a literature review of outcomes that have been used in 
relevant RCTs5–7 augmented by qualitative research 
with patients and caregivers,11 we aimed to include the 
following patient-valued outcomes: acute kidney injury 
(AKI), CKD, end-stage renal disease (ESRD), stroke, 
death, treatment burden, cognitive impairment, inju-
rious falls, hypotension, dizziness, syncope, myocardial 
infarction and heart failure.
evidence selection
Relative effects of blood pressure targets on all outcomes
Systematic search for RCTs on blood pressure targets
We systematically searched for RCTs on blood pres-
sure targets. Since a number of systematic reviews were 
published recently we did not duplicate their entire search 
but identified relevant and recent systematic reviews first 
(figure 1). The detailed search methods are described in 
online supplementary figures S1 and S2, table S1. From 
the systematic reviews and update searches, we identified 
20 RCTs of blood pressure targets in an adult population 
in a non-intensive care setting. We did not use any of the 
meta-analyses of the eight systematic reviews because they 
were either based on or standardised by achieved blood 
pressure, or included trials that did not compare blood 
pressure targets (but eg, one vs two antihypertensives), or 
focused on prehypertension.
Inclusion and exclusion of RCTs on blood pressure targets
We excluded three RCTs with high risk of bias,20–22 as 
assessed with the Cochrane Risk of Bias Tool23 (see 
online supplementary table S2), 12 RCTs that did not 
report enough outcomes or events to judge the bene-
fit-harm balance (eight reported no harm outcomes,24–31 
two reported only CKD as a harm outcome32 33 and one 
reported only sparse data on benefit outcomes,34 and one 
reported only sparse data on harm outcomes35), one RCT 
because the study population was not our target popula-
tion,36 and one because the targets that were compared 
were so high (<150/85 vs <180/105 mm Hg) that they were 
no longer clinically relevant (figure 1 and online supple-
mentary figure S3).37 We included three RCTs: SPRINT,6 
ACCORD,5 which both compared 120 mm Hg versus 
140 mm Hg, and SPS3,7 8 which compared <130 mm Hg 
to 131 to 149 mm Hg. SPRINT included people without 
prior stroke and without diabetes, ACCORD included 
people with diabetes but without prior stroke and SPS3 
included people with lacunar stroke. Notably, we could 
not include dizziness, cognitive impairment and treat-
ment burden in our analysis due to lacking evidence. For 
treatment burden, we considered evidence on increased 
number of pills per day, more doctor appointments or 
burden due to diet and exercise.
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Figure 1 Flow chart of the search for RCTs comparing blood pressure targets based on existing systematic reviews and the 
RCT selection. CKD, chronic kidney disease; RCTs, randomised clinical trials; SR, systematic review.
Considerations on effect modification and heterogeneity
Our search indicated no relevant heterogeneity between 
subgroups in the publications of the trials, however, 
the relative risks reported by the three RCTs sometimes 
differed. In a few cases, this heterogeneity was clearly due 
to sparse data bias, and thus we corrected these estimates 
(table 1).38 39 The remaining heterogeneity was either 
due to different study populations or different outcome 
definitions. As a first step to ensure applicability, we did 
not pool the estimates from SPRINT, ACCORD and SPS3, 
but we applied the estimates to subgroups in our bene-
fit-harm assessment according to the study population 
(ie, SPRINT to people without prior history of stroke and 
diabetes, ACCORD to people with diabetes and without 
stroke and SPS3 to people with stroke, respectively). In 
a second step, we made exceptions for a few outcomes, 
where we applied the estimates from SPRINT instead of 
ACCORD or vice-versa, when differences in estimates 
were judged to be due to the outcome definition rather 
than because of different study populations (table 1).
Because we decided to apply only estimates from 
SPS3 to people with prior history of stroke, and because 
important outcomes for patients with CKD were not 
reported in SPS3, namely AKI and ESRD, we did not 
calculate a benefit-harm balance for people with both a 
history of stroke and CKD, as there would be significant 
uncertainty in the balance.
Baseline incidence of all outcomes
To address baseline incidence of outcomes for people 
with hypertension according to age, gender and prior 
patient history (stroke, diabetes, heart failure and CKD), 
adapting a previously described method,12 we prioritised 
different sources in the following order:
1. US national registries that reflect the target population 
as closely as possible.
2. Observational studies with similar study population as 
the target population.
3. RCTs.
The latter were favoured the least because, compared 
with observational studies, restrictive inclusion criteria or 
recruitment mechanisms can substantially affect baseline 
incidence rates. To avoid inconsistency, we based as many 
estimates as possible on prediction models and incidence 
tables based on the Atherosclerosis Risk in Communi-
ties (ARIC) study.40–44 Assumptions about additional risk 
factors beyond those defining the subgroups were neces-
sary when prediction models included other risk factors 
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Table 1 Incidence rate ratios for the comparison of different systolic blood pressure targets
Targets (mm Hg)
SPRINT ACCORD SPS3
<120 vs <140 <120 vs <140 <130 vs 130–149
Target population in benefit-harm assessment
Prior history of:
  Diabetes No Yes Yes or no
  CKD Yes or no Yes or no No
  Stroke No No Yes
Benefit outcomes
  Mortality 0.74 (0.60, 0.91) 1.05 (0.83, 1.32) 1.06 (0.80, 1.41)
  Myocardial infarction 0.84 (0.63, 1.11) 0.87 (0.68, 1.11) 0.91 (0.57, 1.47)
  Heart failure 0.62 (0.44, 0.86) 0.93 (0.68, 1.26) *
  Stroke 0.89 (0.62, 1.27) 0.58 (0.38, 0.89) 0.83 (0.65, 1.06)
  ESRD 0.59 (0.18, 1.80) 0.59 (0.18, 1.80)†† *
Harm outcomes
  CKD 1.91 (1.35, 2.70)† 1.91 (1.35, 2.70) 1.41 (1.15, 1.67)‡
  Hypotension 1.70 (1.31, 2.22) 2.61 (1.21, 5.66)§ 1.55 (0.78, 3.10)
  Syncope 1.44 (1.13, 1.85) 1.44 (1.13, 1.85) 2.33 (0.71, 6.95)
  Injurious falls 1.01 (0.86, 1.18) 1.01 (0.86, 1.18)¶ 1.07 (0.54, 2.10)**
  AKI 1.70 (1.35, 2.15) 1.70 (1.35, 2.15)¶ *
  Dizziness – – –
  Treatment burden – – –
  Cognitive impairment – – –
Incidence rate ratios calculated based on number of events and number of patient-years in each trial arm. Outcomes are grouped into benefit 
outcomes and harm outcomes according to the SPRINT estimate. Estimates larger than one imply that the outcome occurs more frequently 
with the lower blood pressure target. Conversely, estimates lower than one mean the lower blood pressure target reduces the risk for that 
outcome.
*SPS3 did not report heart failure, ESRD and AKI, and we did not extrapolate from SPRINT or ACCORD because the SBP targets were 
different.
†We used the CKD estimate from ACCORD instead of SPRINT, because an incident estimated glomerular filtration rate <30 mL/min/1.73 m2 is 
more likely symptomatic and patient-important than <60 mL/min/1.73 m2.
‡The estimate for CKD in SPS3 is an OR, extracted from a posthoc analysis of the trial data.
§Corrected for sparse data bias with a prior incidence rate ratio between 1 and 5.
¶We used estimates from SPRINT for injurious falls and AKI because ACCORD did not report them, and we used the estimate from SPRINT 
for syncope because we assessed the ACCORD estimate as high risk of bias.
**Corrected for sparse data bias with a prior incidence rate ratio between 0.5 and 2. We could not include dizziness, treatment burden and 
cognitive impairment in our main analysis.
††We used the ESRD estimate from SPRINT instead of ACCORD because SPRINT considered only incident ESRD in patients who had prior 
history of CKD.
AKI, acute kidney injury; CKD, chronic kidney disease; ESRD, end-stage renal disease; OR, odds ratio; SBP, systolic blood pressure.
(see online supplementary table S3 for an overview on 
which subgroups affected the baseline incidence of which 
outcomes). We also developed a web-calculator in which 
the impact of all risk factors can be explored.
Relative importance of outcomes from patient preference survey
We surveyed people with MCC and hypertension in the 
USA using best-worst scaling (Aschmann et al, ‘Outcome 
preferences of older people with multiple chronic condi-
tions and hypertension: A cross-sectional survey using 
best-worst scaling’, submitted), a preference elicitation 
method which provides weights for outcomes relative to 
one another and is easy to understand.45 Both the Insti-
tutional Review Boards of Johns Hopkins University and 
Kaiser Permanente Colorado approved the survey. In 
brief, we sent paper surveys to members of Kaiser Perma-
nente Colorado aged 60 or older who had hypertension 
and at least two other chronic conditions. We presented 
respondents with 11 blocks of five outcomes and asked 
them which they would worry about most, and which 
least. We analysed 207 responses with a conditional logit 
model. Based on this, we used the following weights in 
the main analysis: death (1), myocardial infarction (0.66), 
heart failure (0.65), stroke (0.76), ESRD (0.47), CKD 
(0.45), hypotension (0.01), syncope (0.11), injurious falls 
(0.02), AKI (0.33), treatment burden (0). Respondents 
were aged 60 to 97, and the most common conditions 
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additionally to hypertension were hyperlipidaemia, CKD 
and diabetes. They were similar to non-respondents in 
terms of age, number of comorbidities, gender, race and 
ethnicity. Because baseline characteristics were not associ-
ated with different preferences, we applied the weights to 
all subgroups in the benefit-harm assessment, including 
people younger than 60 years.
statistical analysis
We calculated the number of expected events over 5 years 
in a population of 10 000 based on the baseline incidence 
and relative effects.13 Longer time horizons may be more 
relevant, but the RCTs were too short to inform relative 
risks and incidence rates for longer than 5 years, especially 
for adverse events like AKI or CKD. All-cause mortality 
was considered a competing risk for all other outcomes. 
We considered statistical uncertainty of estimates in rela-
tive effects and distributions in baseline incidences (due 
to distributions of risk factors accounted for in prediction 
models) in 100 000 repetitions in the analysis (equations 
in online supplementary file).
Subsequently, we calculated the Gail index13 as the 
weighted difference in event numbers: the difference in 
number of expected events for each outcome is multi-
plied with its relative importance, and the weighted differ-
ences are summed across outcomes. For example, if we 
only considered stroke and CKD, and if we expect 58 less 
strokes but 201 more CKD events with the lower target, 
the Gail index would be (−58)×0.76+201×0.45=+46, that 
is, there would be 46 more events of ‘importance 1’ 
with the lower target, thus the higher target would be 
better. However, to account for statistical uncertainty, we 
repeated the calculation of the Gail index 100 000 times. 
In the example above, this would yield a distribution with 
a mean Gail index of +46.
We then calculated the probability that one SBP target 
is better than another. In the example, the probability 
that the higher target is better is the proportion of the 
repetitions when the Gail index was greater than zero. 
For example, a probability of 0.7 that the higher target is 
better inversely means the probability is 0.3 that the lower 
target is better. We categorised the probabilities into 
greater than 0.6 (target better than reference), smaller 
than 0.4 (target worse than reference) and in between 
(unclear which is better).
To define a range of possible estimates of the bene-
fit-harm balance, we performed two additional analyses 
– one favouring the lower and one the upper target – 
taking into account (non-statistical) uncertainty in the 
baseline incidence.
sensitivity analyses
To investigate the effect of individual preferences, we 
generated preference values for each respondent in the 
survey based on individual best-minus-worst scores (a 
count measure). In sensitivity analysis 1, we applied the 
individual preference values. In sensitivity analysis 2, we 
additionally included treatment burden, assuming 20% 
of people have more treatment burden with the lower 
target than with 140 mm Hg. In sensitivity analyses 3 to 
5 we assigned different population preference weights 
(preferences on an aggregate level, see online supple-
mentary table S4).
software
We performed calculations in R V.3.3.1.
Patient and public involvement
The research question was identified as a priority ques-
tion by people with MCC and caregivers.11 A preference 
survey among people with MCC informed on applicable 
weights for outcomes in the benefit-harm assessment. 
Four patient and caregiver co-investigators were involved 
throughout the project, starting with the conception of 
the study. In particular, they helped in the development 
of the survey, and contributed to framing the conclusions 
and to drafting a summary of the results that was sent to 
all survey respondents. They continue to help with the 
dissemination of the study results.
results
Table 2 shows the expected number of events over 5 years 
per 10 000 people, across three age groups in people 
without prior history of stroke (mixed population with 
and without diabetes, CKD and heart failure) with SBP 
targets of 140 mm Hg and 120 mm Hg. In 50 to 64 year 
olds 361 deaths are expected per 10 000 people over 5 
years with a target of 140 mm Hg, and 281 deaths are 
expected with a target of 120 mm Hg. Hence, 80 deaths 
per 10 000 people 50 to 64 years old over 5 years can be 
prevented by targeting 120 mm Hg instead of 140 mm 
Hg (corresponding to a number needed to treat of 125). 
Targeting 120 mm Hg would result in higher incidence of 
CKD, AKI, hypotension, syncope and injurious falls. For 
example, in the same group of 10 000 people, 118 addi-
tional cases of incident CKD would be caused by targeting 
120 mm Hg instead of 140 mm Hg (corresponding to a 
number needed to harm of 85).
benefit-harm balance of blood pressure targets in subgroups 
with population weights
We explored 120 subgroups defined by age (50 to 64, 65 to 
74, 75 to 84 years), gender (male, female), prior history of 
diabetes (yes, no), CKD (no: estimated glomerular filtra-
tion rate >60, stage 3A: 45 to 59, stage 3B: 30 to 44, stage 
4: 15 to 29 mL/min/1.73 m2), chronic heart failure (yes, 
no) and stroke (yes, no). Furthermore, a web-calculator is 
available with which the impact of further risk factors and 
individual preferences can be explored (https://www. 
ebpi. uzh. ch/ en/ translational_ research/ archive_ trans-
lational_ research/ archive_ health_ research_ methods/ 
benefit_ harm_ assessments. html).
In table 3, the probability that a lower SBP target of 120 
or <130 mm Hg is better than a higher target of 140 or 131 
to 149 mm Hg is shown for all subgroups, considering all 
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Table 2 Number of events in 10 000 persons without prior history of stroke over 5 years
Target (mm Hg)
Age 50–64 Age 65–74 Age 75–84
140 120 Difference 140 120 Difference 140 120 Difference
Death 361 281 +80 852 694 +158 2037 1661 +376
Myocardial infarction 187 158 +29 320 274 +46 462 401 +61
Heart failure 195 131 +64 567 402 +165 763 543 +220
Stroke 104 91 +13 246 208 +38 443 385 +58
ESRD 50 32 +18 68 43 +25 60 39 +21
CKD 126 244 −118 192 371 −179 209 410 −201
AKI 194 332 −138 189 325 −136 177 308 −131
Hypotension 253 463 −210 285 551 −266 382 733 −351
Syncope 292 424 −132 275 401 −126 552 809 −257
Injurious falls 528 535 −7 728 741 −13 2022 2082 −60
Number of expected events in 10 000 people without prior history of stroke over 5 years with a target of 140 mm Hg or 120 mm Hg, and the 
difference in numbers of events between the two targets.
AKI, acute kidney injury; CKD, chronic kidney disease; ESRD, end-stage renal disease.
available outcomes and accounting for statistical uncer-
tainty of the estimates. In the main analysis, the proba-
bility that the lower target is better than the higher target 
was greater than 0.6 for 72 of 120 subgroups (blue cells: 
additional analyses with different assumptions for base-
line incidences also yielded a probability above 0.6, see 
online supplementary table S5). Notably, this was true for 
all male subgroups aged 75 to 84 without prior stroke, 
and for all subgroups of people with prior stroke aged 50 
to 64 years.
The probability that 120 mm Hg is better than 140 mm 
Hg was less than 0.4 for eight subgroups – these eight 
subgroups were women aged 50 to 74 who have a prior 
history of CKD stage 3B or 4 and without history of stroke 
(orange cells). The different results between subgroups 
partly arise due to lower cardiovascular risk in women and 
higher risk of AKI in people with CKD. In older people, 
the increased incidence of cardiovascular events and 
death drive the benefit-harm balance (data not shown). 
In subgroups with prior history of stroke, the probability 
that <130 mm Hg is better than 131 to 149 mm Hg was 
never lower than 0.4.
The mean index describes the clinical relevance of 
net benefit or harm as the mean number of events (with 
equivalent importance as death) that were prevented or 
caused by targeting 120 mm Hg instead of 140 mm Hg 
(see online supplementary table S6). Across subgroups, 
the maximum was 1133 with a possible range of 828 to 
1193 (based on different assumptions for baseline risks) 
prevented events among 10 000 people over 5 years, 
attained in the subgroup of men aged 75 to 84, without 
history of stroke, but with history of diabetes, heart failure 
and stage 3A CKD.
sensitivity analyses considering individual preferences
The impact of the variation in individual preferences 
(sensitivity analysis 1) is shown in figure 2. For eight 
subgroups the probability that the lower target is better 
was always greater than 0.6 – that is, for these subgroups, 
with every possible preference found in the survey, the 
better target was always 120 mm Hg. In many subgroups 
without prior history of stroke, especially with ages 50 to 
64 years, the probability of 120 mm Hg to be better than 
140 mm Hg almost spanned the full range of 0 to 1, as 
indicated by the whiskers in figure 2. This meant that 
any probability of 120 mm Hg being better or worse was 
possible, and depended on the preference of the indi-
vidual. For example, using weights from a survey respon-
dent who worried most about ESRD, followed by stroke 
and AKI, we calculated a probability of 0.05 that 120 mm 
Hg is better for a woman with diabetes, stage 4 CKD and 
heart failure but no prior history of stroke. For the same 
subgroup, using weights from a survey respondent for 
whom myocardial infarction, heart failure and stroke were 
the most worrisome outcomes, the probability was 0.95 
that 120 mm Hg is better. For people with prior history 
of stroke, the range of the probability that <130 mm Hg 
is better than 131 to 149 mm Hg was also wide. Thus, the 
probability that <130 mm Hg is better was dependent on 
the preferences of the individual. Sensitivity analyses 3 to 
5 (see online supplementary tables S7–10) confirmed the 
results of sensitivity analysis 1. A sensitivity analysis with 
equal weights for all outcomes is shown in online supple-
mentary table S11.
sensitivity analyses considering individual preferences and 
additionally including treatment burden
In a further sensitivity analysis (sensitivity analysis 2), we 
added treatment burden, one of the patient-important 
outcomes for which we did not have data. Based on the 
preference survey, we assumed 20% of people would 
have more treatment burden with a lower blood pressure 
target due to needing an additional medication. While 
considering treatment burden decreased the median 
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Table 3 Benefit-harm balance of different systolic blood 
pressures: probability that the lower target is better
Diabetes CKD CHF
Age
50–64
Age
65–74
Age
75–84
120 vs 140 mm Hg, SPRINT Probability that lower target is 
better in men without stroke & 
without diabetes
No No No 0.96 1.00 1.00
No No Yes 0.72 0.91 0.96
No Stage 3A No 0.96 1.00 1.00
No Stage 3B No 0.53 0.92 0.99
No Stage 4 No 0.48 0.80 0.97
No Stage 3A Yes 0.87 0.95 0.97
No Stage 3B Yes 0.43 0.74 0.89
No Stage 4 Yes 0.41 0.64 0.82
120 vs 140 mm Hg, SPRINT In women without stroke & 
without diabetes
No No No 0.63 0.98 1.00
No No Yes 0.27 0.75 0.94
No Stage 3A No 0.77 1.00 1.00
No Stage 3B No 0.12 0.69 0.99
No Stage 4 No 0.26 0.55 0.93
No Stage 3A Yes 0.57 0.92 0.97
No Stage 3B Yes 0.06 0.34 0.80
No Stage 4 Yes 0.20 0.31 0.60
120 vs 140 mm Hg, ACCORD In men without stroke & with 
diabetes
Yes No No 0.71 0.89 0.93
Yes No Yes 0.89 0.97 0.98
Yes Stage 3A No 0.92 0.95 0.96
Yes Stage 3B No 0.66 0.85 0.91
Yes Stage 4 No 0.45 0.74 0.89
Yes Stage 3A Yes 0.98 0.99 0.99
Yes Stage 3B Yes 0.88 0.97 0.97
Yes Stage 4 Yes 0.71 0.93 0.96
120 vs 140 mm Hg, ACCORD In women without stroke & with 
diabetes
Yes No No 0.37 0.70 0.81
Yes No Yes 0.69 0.89 0.92
Yes Stage 3A No 0.66 0.85 0.88
Yes Stage 3B No 0.31 0.54 0.73
Yes Stage 4 No 0.33 0.51 0.69
Yes Stage 3A Yes 0.92 0.97 0.97
Yes Stage 3B Yes 0.63 0.84 0.91
Yes Stage 4 Yes 0.57 0.78 0.88
<130 vs 131–149 mm Hg, 
SPS3
In men with stroke
No No No 0.70 0.58 0.44
No No Yes 0.68 0.60 0.49
Yes No No 0.68 0.61 0.48
Yes No Yes 0.66 0.59 0.54
Continued
Diabetes CKD CHF
Age
50–64
Age
65–74
Age
75–84
<130 vs 131–149 mm Hg, 
SPS3
In women with stroke
No No No 0.71 0.59 0.40
No No Yes 0.69 0.60 0.46
Yes No No 0.69 0.60 0.46
Yes No Yes 0.67 0.62 0.50
The probability that the lower target (120 mm Hg or <130 mm Hg) is 
a better target than the higher target (140 mm Hg or 131 to 149 mm 
Hg) is shown for all subgroups (calculated from 100 000 repetitions). 
Subgroups are presented according to which RCT was used to inform 
the analysis and what targets were compared. A probability of 0.5 
means that both targets have the same benefit-harm balance. Blue 
colour indicates the lower target was better also in additional analysis 
with different assumptions for baseline incidences, and orange colour 
indicates the higher target was better also in the additional analyses. 
We did not calculate the benefit-harm balance of different blood 
pressure targets for people with prior history of stroke and CKD, 
because renal outcomes that would be important for people with CKD, 
but rare for people without CKD, were not reported by SPS3.
CHF, chronic heart failure; CKD, chronic kidney disease; RCT, 
randomised clinical trial.
Table 3 Continued
probability that the lower target is better, it also widened 
the range of the probability in most subgroups (see online 
supplementary figure S4).
DIsCussIOn
Our analyses showed that the benefit-harm balance of SBP 
targets in people with MCC and hypertension depends 
on age, gender, comorbidities (history of diabetes, CKD, 
heart failure and stroke) and largely on the outcome pref-
erences of patients. Our results highlight the importance 
of performing qualitative and quantitative preference 
surveys to identify patient-important outcomes and deter-
mine weights, and to assess the impact of different pref-
erences on the benefit-harm balance. Preferences should 
be assessed in the target population, and it is known that 
physicians can have different preferences.46 If there is 
large variation in individual preferences, there are two 
possible consequences. First, it is possible that one inter-
vention is still consistently better, as was true for a few of 
the subgroups in our analyses. Second, the balance can be 
preference-sensitive, as was true for most of the subgroups 
in our analyses, where the probability of one target being 
better than the other spanned almost the full range of 0 
to 1, depending on the individual’s preferences. In this 
case, shared decision-making with explicit determina-
tion of the individual’s preferences may be appropriate. 
Further research is needed on how to elicit individual 
preferences in the clinic. Patient decision aids with an 
integrated calculation of the benefit-harm balance may 
help in shared decision-making when the benefit-harm 
balance is preference-sensitive and depends on prior 
medical history. The web-calculator that we provided as 
an addendum is not ready to be used as a decision aid 
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Figure 2 Sensitivity analysis 1 - impact of variation in preferences between individuals. Distribution (full range, IQR and 
median) of the benefit-harm balance with 207 different sets of weights, according to the preferences of all 207 individuals in the 
preference survey. In almost all subgroups, the variation in individual preferences lead to wide ranges of balances, with some 
favouring a lower target (dark grey shaded), and some favouring a higher target (light grey shade). In eight subgroups without 
prior history stroke, even with the most extreme preferences, the better target was always 120 mm Hg. CHF, Chronic heart 
failure; CKD, Chronic kidney disease; DM, Diabetes mellitus type 2; IQR, interquartile range.
– for this, the tool would need to be extensively tested 
with patients and clinicians. It would also need to convey 
the uncertainty in the benefit-harm balance, for example 
showing estimates of the benefit-harm balance using 
different prediction models for baseline incidences.
While for most subgroups the benefit-harm balance 
of SBP targets was preference-sensitive, and shared deci-
sion-making would accordingly be appropriate, for a few 
subgroups, one target was clearly better. We identified 
eight subgroups without prior history of stroke for which 
a target of 120 mm Hg was better even for extreme pref-
erences. The benefit-harm balance shifted only when we 
assumed that individuals perceived the additional treat-
ment burden as high. The absolute benefit was relatively 
high, with 436 to 1133 events of equivalent importance to 
death prevented in 10 000 people over 5 years.
Two guidelines about blood pressure targets have been 
published in 2017 from US organisations: the Amer-
ican College of Cardiology/American Heart Association 
(ACC/AHA)1 and the American College of Physicians 
(ACP).2 Neither performed a quantitative benefit-harm 
assessment with explicit weights. Their recommendations 
differ, both from each other and from our results, mostly 
due to four reasons. First, the ACC/AHA guideline did 
not consider any adverse events except the combined 
outcome ‘renal outcomes’ (including ESRD and AKI) – 
that is, the guideline made a trade-off between cardiovas-
cular benefit and renal harm, but did not take into account 
other harms of lower targets like syncope. Second, the 
ACC/AHA guideline considered only relative risk reduc-
tions in the underlying systematic review, and it is unclear 
how it considered absolute effects of different targets. 
Third, both guidelines assessed achieved blood pressure 
additionally, which we did not consider, because these 
values can deviate from the target for a large number of 
reasons, and were not randomised in the trials. Fourth, 
the implicit weights that were assigned differed, as we 
interpret from the published rationale. The ACC/AHA 
guideline implicitly weighs cardiovascular events more 
than possible adverse events – which may reflect the pref-
erences of many, but not all patients. The ACP guideline 
implicitly weighs treatment burden and adverse events 
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more than the ACC/AHA guideline, and states that while 
<140 mm Hg would further reduce the cardiovascular risk 
in people aged 60 or older, the additional benefit is small 
and inconsistent across outcomes.
Notwithstanding our different methods and results, we 
agree on many points with both guidelines. Our results 
indicate that indeed individual assessment of benefits 
and harms in people with MCC is important, like the 
ACP guideline recommends, and individual preferences 
should be considered. The ACC/AHA guideline sees 
significant benefit of a lower SBP target, but adjusts the 
target of 120 mm Hg to 130 mm Hg because in real-world 
practice, achieved blood pressure measurements tend to 
be higher than in the setting of a RCT.1 10 Similarly, our 
results indicate that a SBP target of 120 mm Hg has signif-
icant potential to benefit subgroups without prior history 
of stroke and no CKD of stage 3B or higher. In contrast, a 
SBP target of 140 mm Hg was better for some subgroups 
of women aged 50 to 64 with CKD stages 3B or 4. The 
ACC/AHA guideline recommends a target of 130 mm Hg 
for people with prior history of CKD, which may reflect 
that most cases of CKD are of stage 3A,44 where lower 
targets may be more beneficial.
Our approach to identify the optimal SBP target 
for people with MCC had several strengths. First, we 
predefined the subgroups of relevance for people with 
MCC. Second, in collaboration with patients and care-
givers, we identified patient-important outcomes, and 
regularly informed them about the progress to assure 
the results would be meaningful to people with MCC. 
Third, we performed sensitivity analyses with different 
weights and could show in which subgroups the bene-
fit-harm balance could shift, and in which the balance 
was relatively stable. Finally, to quantify the uncertainty in 
the probability that one target is better than another, we 
performed additional analyses including all assumptions 
that we were unsure about, to get a conservative estimate 
of what the range of possible estimates may be.
Our analyses emphasise where most uncertainty 
remains. Evidence is lacking for cognitive impairment 
and for mild adverse events, such as daily mild dizziness. 
SPS3 did not report heart failure, ESRD and AKI, which 
adds uncertainty for people with prior history of stroke. 
As these outcomes are particularly important in people 
with CKD, the benefit-harm balance for people with prior 
history of stroke and CKD cannot be judged. People 
with heart failure were not well represented in the trials, 
therefore, uncertainty is larger for subgroups with heart 
failure. Furthermore, our main analysis did not include 
treatment burden, as we would have needed to know how 
many more people experience significantly more treat-
ment burden with lower targets. However, our analyses 
indicate treatment burden may not shift the benefit-harm 
balance drastically on average, but it may increase the 
impact of variation in individual preferences.
Our model puts the most applicable, valid and precise 
evidence into context. To address this gap in evidence 
in a study instead, a very large RCT would be needed, 
in which older people with MCCs – and in different 
combinations of MCCs – are well represented, and 
which includes a preference survey among participants. 
Chances are no such RCT will ever be performed. A 
major limitation is, therefore, that it is difficult to confirm 
the results of the model. However, in the absence of a 
study, a model that follows a systematic approach based 
on epidemiological principles and the available clinical 
evidence is necessary to inform this question. We aimed 
to assess the benefit-harm balance of different blood 
pressure targets; how these targets are best achieved was 
out of scope. Techniques to measure the blood pressure 
differed between trials and may differ between trials and 
clinical practice.1 10 Therefore, we presented the results 
using different trials separately, because their targets 
may be interpreted differently. As the target setting was 
the USA and we used baseline risks applicable there, the 
benefit-harm balance of SBP targets may be different in 
other countries.
COnClusIOns
In conclusion, the lower SBP targets have significant 
potential to benefit people with MCC who tolerate antihy-
pertensive treatment, especially among those who do not 
have CKD stage 3B or higher and no history of ischaemic 
stroke. The potential benefit is largest in people older 
than 75 who do not have a history of ischaemic stroke. 
Shared decision-making should take place, as individual 
preferences can have a substantial influence on the bene-
fit-harm balance.
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